

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

<p>(51) International Patent Classification <sup>5</sup> :  <b>C12N 15/00, C07H 17/00, A61K 48/00</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 94/13793</b></p> <p>(43) International Publication Date: <b>23 June 1994 (23.06.94)</b></p>
<p>(21) International Application Number: <b>PCT/US93/11144</b></p> <p>(22) International Filing Date: <b>16 November 1993 (16.11.93)</b></p> <p>(30) Priority Data:  <b>989,852                      4 December 1992 (04.12.92)      US</b></p> <p>(60) Parent Application or Grant  (63) Related by Continuation  <b>US    989,852 (CIP)</b>  <b>Filed on                                      4 December 1992 (04.12.92)</b></p> <p>(71) Applicant (for all designated States except US): <b>APOLLON, INC. [US/US]; One Great Valley Parkway, Suite 30, Malvern, PA 19355 (US).</b></p> <p>(72) Inventors; and  (75) Inventors/Applicants (for US only): <b>PACHUK, Catherine, J. [US/US]; 223 Scottsdale Road, B-511, Lansdowne, PA 19050 (US). CONEY, Leslie, R. [US/US]; 1000 Conestoga Road, A-201, Rosemont, PA 19010 (US). OAKES, Fred, T. [US/US]; 24 Oak Hill Circle, Malvern, PA 19355 (US).</b></p>		<p>(74) Agents: <b>ELDERKIN, Dianne, B. et al.; Woodcock Washburn Kurtz Mackiewicz &amp; Norris, One Liberty Place - 46th floor, Philadelphia, PA 19103 (US).</b></p> <p>(81) Designated States: <b>CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)</b></p> <p><b>Published</b>  <i>With international search report.</i></p>
<p>(54) Title: <b>COMPOUNDS AND METHODS FOR THE TREATMENT OF LEUKEMIAS</b></p>		
<p>(57) Abstract</p> <p>Ribozymes are provided in which the ribozymes have a catalytic sequence, two legs and at least one anchor sequence complementary to the substrate mRNA at a location that can be noncontiguous with the portions of the substrate mRNA complementary to the legs. In certain preferred embodiments, ribozymes capable of cleaving the L6 mRNA or both the L6 and K28 mRNAs are provided. Methods are provided for the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) patients having the L6 and K28 translocations and, therefore, the L6 mRNA. Additionally, combination treatments comprising components specific for both the K28 and L6 mRNAs are provided. Combination treatments are also provided for those patients which express c-myc in combination with K28 and/or L6 mRNAs. Methods of treatment include, for example, administration of ribozymes and antisense oligonucleotides directed against these mRNAs.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LV	Latvia	SN	Senegal
CN	China	LE	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

**COMPOUNDS AND METHODS FOR  
THE TREATMENT OF LEUKEMIAS**

**FIELD OF THE INVENTION**

The present invention provides ribozymes having an anchor sequence capable of anchoring the ribozyme to a region of the substrate mRNA that may be noncontiguous with the region of substrate mRNA complementary to a leg of the ribozyme. Certain preferred embodiments of the present invention include ribozymes capable of cleaving the L6 fusion mRNA or both the L6 and K28 mRNAs expressed by the hematopoietic cells of some CML and ALL patients. The present invention also furnishes methods of treating leukemias using oligonucleotide therapeutics.

**BACKGROUND OF THE INVENTION**

The potential use of ribozymes as pharmaceuticals is an exciting prospect. An important requirement for the development of ribozyme pharmaceutical products is the ability to specifically target a ribozyme to a cellular RNA of interest. This can be especially difficult when designing a ribozyme for a chimeric RNA molecule that is homologous to a second RNA molecule, particularly if cleavage of the second RNA is detrimental to the host. It may be equally difficult to target an RNA molecule that is folded in a way that prevents ribozyme interactions at or near the ribozyme cleavage site. We have encountered both of these problems in our attempts to design ribozymes that are specific for an aberrant mRNA associated with chronic myelogenous leukemia (CML).

- 2 -

Chronic Myelogenous Leukemia (CML) and acute lymphocytic leukemia (ALL) represent two different types of leukemias. CML is a chronic myeloproliferation disorder associated with the cytogenic marker called the Philadelphia chromosome (Nowell, P.C. and Hungerford, D.A., *Science* 1960, 132, 1497) in approximately 95% of patients. The Philadelphia chromosome is a chromosomal abnormality resulting from reciprocal translocations between chromosomes 9 and 22 (Mercola, M. et al., *Science* 1933, 221, 663).

10           The breakpoints on chromosome 22 are clustered in a 6 Kb region termed the breakpoint cluster region (*bcr*) (Groffen, J. et al., *Cell* 1984, 36, 93-99), while on chromosome 9, the breakpoints are scattered throughout a 90 Kb region upstream from *c-abl* exon 2 (Heisterkamp, N. et al., *Nature* 1983, 306, 239-242). The resultant fusion transcripts, which are about 8.5 kb long, contain *bcr* sequences upstream and *abl* sequences downstream.

          The cellular gene *abl*, a highly conserved gene, represents the progenitor of the viral transforming gene (*v-abl*) of Abelson leukemia virus. *v-abl* confers to Abelson leukemia virus the ability to transform a broad range of hematopoietic cell types. Transformation is mediated by a tyrosine kinase encoded by the viral genome, composed of *v-abl* polypeptide attached at its N-terminus to viral gag polypeptide. The human *abl* gene was mapped to chromosome 9, and is expressed as a 145 kd protein having tyrosine kinase activity. Misregulation of *abl* is implicated in CML in humans. Shtivelman et al., *Cell* 1986, 47, 277-284.

          The various 9:22 translocations associated with the Philadelphia chromosome can be subdivided into two types: K28 translocations and L6 translocations. In the K28 mRNA, *abl* exon 2 is linked to *bcr* exon 3. In the L-6 mRNA, *abl* exon 2 is linked to *bcr* exon 2. *C-myc* mRNA is pertinent for blast crisis in CML.

35           A third type of 9:22 translocation has also been identified. The chromosome 9 breakpoints specific for this type of translocation are located 5' of the L6 breakpoints.

- 3 -

The presence of this abnormal chromosome, however, is associated with the establishment of acute lymphocytic leukemia (ALL) not CML. Salleri et al., *Blood* 1990, 75, 1146-1153. Further, the K28 and L6 mRNAs have been associated with some patients with ALL.

Much emphasis has been placed on the role of mRNA K28 and the establishment of CML. (Shtivelman, E. et al., *Cell* 1986, 47, 277-284; Kubonishi, I. and Miyoshi, I., *Int. J. Cell Cloning* 1983, 1, 105-117; Shtalrid, M.T. et al., *Blood* 1988, 72, 485-490; Mills, K.I. et al., *Blood* 1988, 72, 1237-1241).

In the K28 translocations, the chromosomal 22 breakpoints lie between *bcr* exons 3 and 4 (Shtivelman, E. et al., *Cell* 1986, 47, 277-284). Transcription through this region yields an mRNA which can be alternatively spliced to yield two distinct mRNAs (Shtivelman, E. et al., *Cell* 1986, 47, 277-284): mRNA K28 and mRNA L6. In mRNA K28, *bcr* exon 3 is fused to *abl* exon 2, while in mRNA L6, *bcr* exon 2 is fused to *abl* exon 2. Importantly, the mRNA yielded can change during the course of disease. In the L6 translocations, the chromosomal breakpoints lie between *bcr* exons 2 and 3 (Shtivelman, E. et al., *Cell* 1986, 47, 277-284). Transcription through this region yields only one species of mRNA, mRNA L6. The K28 and the L6 mRNAs encode a protein with an aberrant tyrosine kinase activity which is unique to CML cells and which is believed to play a key role in the establishment of CML. McLaughlin et al., *Proc. Nat'l. Acad. Sci.* 1987, 84, 6558-6562.

To date, bone marrow transplantation has been the most effective way to treat CML. Nonetheless, using a more sensitive technique, it has been demonstrated that in some patients receiving ablative radiation and/or chemotherapy followed by bone marrow transplantation, residual leukemia cells may persist. Researchers have detected residual *bcr-abl* mRNA in patients following bone marrow transplantation in a study using a more sensitive PCR assay. Snyder et al., *Transplantation* 1991, 51, 1033-1040. There remains an unmet

- 4 -

need in reducing the level of mRNAs and their protein products implicated in leukemias in the treatment of CML and ALL. These mRNAs include the *bcr-abl* transcripts such as the K28 and L6 mRNAs, as well as *c-myc* mRNA.

5           Ribozymes offer an attractive alternative. Chimeric RNAs, such as those occurring in CML, can be ideal candidates for ribozyme targeting particularly when a ribozyme cleavage site is located within 2 or 3 nucleotides of the chimeric junction, i.e. near the junction. In this  
10 case a ribozyme can be targeted specifically to the chimeric molecule but not the non-chimeric molecule by specifying that 1) ribozyme sequences 5' of the catalytic region be complementary to chimeric RNA sequences located immediately  
15 3' of the cleavage site, and 2) ribozyme sequences 3' of the catalytic region be complementary to chimeric sequences immediately 5' of the cleavage site. The specificity of the ribozyme is thus, presumably, maintained and the potentially harmful results of non-specific ribozyme cleavage can be avoided.

20           However, not all chimeric mRNAs exhibit a convenient site for ribozyme cleavage so near to the junction site. Examination of the L6 *bcr-abl* mRNA sequence reveals that the closest "NUX" ribozyme cleavage sites in the vicinity of the *bcr-abl* junction are located 7, 8, and  
25 19 nucleotides away from the junction (see Figure 1b). It is not feasible to target any of these sites for ribozyme cleavage in the manner described because such ribozymes would likely also cleave normal *abl* mRNA or normal *bcr* mRNA. In addition, computer predictions for the secondary  
30 structures of L6 *bcr-abl* mRNA suggest that these sites may be inaccessible to conventional ribozymes. Accordingly, we initiated new approaches to the design of ribozymes specific for L6 *bcr-abl* mRNA.

          Reddy, et al., WO 92/00080, published January 9,  
35 1992, report a ribozyme capable of cleaving the hybrid *bcr-abl* "gene" of CML at or near the breakpoint. The translocation product targeted was not specified, and the

implication was that only one translocation occurred. Nevertheless, from sequence complementarity, it appears that the ribozyme of Reddy was directed against the K28 translocation. This translocation exhibits a convenient  
5 site near the junction for conventional ribozyme cleavage. Tests verifying specificity of the ribozyme for hybrid *bcr-abl* were not provided.

As noted previously, the particular message transcribed by K28 can change during the course of disease.  
10 Further, certain CML patients express the L6 mRNA either alone or in addition to the K28 mRNA. Shtivelman et al., *Cell* 1986, 47, 277-284. There remains an unsolved problem which has not been addressed; the L6 mRNA. The L6 mRNA will most likely be unaffected by treatments designed solely to  
15 target the K28 mRNA. Further, there is an unmet need in targeting the c-myc mRNA in conjunction with the *bcr-abl* transcripts.

The present invention provides oligonucleotide therapeutics and methods of treating CML and ALL whereby the  
20 aforementioned transcripts are specifically targeted. The present invention also provides ribozymes capable of cleaving L6 mRNA, or both L6 and K28 mRNA.

The present invention also addresses, in general, an unmet need for ribozymes capable of cleaving a target  
25 mRNA in which the catalytic recognition sequence is located at a distance from the nucleation site, the junction of a chimeric target mRNA, or in which catalytic recognition sequences are not readily accessible due to secondary structure. The ribozymes of the present invention are  
30 useful, for example, in the treatment of diseases involving translocations, such as CML, ALL and follicular lymphoma.

#### SUMMARY OF THE INVENTION

We have developed a generic approach for ribozyme targeting using a *bcr-abl* fusion mRNA associated with the  
35 establishment of chronic myelogenous leukemia (CML) as a model. Using this approach, we successfully directed

- 6 -

ribozyme nucleation to a site on a *bcr-abl* RNA substrate that is distant from the cleavage site. Generally, the nucleation sites are immediately contiguous to the cleavage site and the legs of the ribozyme can perform the

5 nucleation, i.e., initial contact with the substrate facilitating subsequent hybridization, twisting, and cleavage. However, sometimes, there are no sites immediately contiguous to the cleavage site available for

10 nucleation. With the ribozymes of the invention, non-contiguous regions of the substrate RNA can therefore be utilized for the separate events of ribozyme nucleation and ribozyme cleavage. This approach has led to the development of a series of ribozymes specific for the L6 and K28 *bcr-abl* fusion mRNAs. These ribozymes were targeted to the L6 *bcr-*

15 *abl* RNA via an anchor sequence complementary to the *bcr* sequence that is proximal to the *bcr-abl* junction. Cleavage by these ribozymes occurred at a downstream site located within an *abl* specific sequence in the fusion mRNAs. Normal *abl* and *bcr* substrate RNAs were not cleaved. The approach

20 of our invention has made it possible to increase the specificity of ribozyme cleavage for a chimeric RNA. In addition, this same approach allows a ribozyme to cleave at a site that is otherwise inaccessible due to the secondary structure of the substrate RNA or, in the case of chimeric

25 RNA, at a site distant from the junction.

This invention provides ribozymes capable of cleaving an L6 mRNA having *bcr* exon 2 sequences fused at a junction to *abl* exon 2 sequences. These ribozymes comprise nucleotides or derivatives thereof having at least one

30 region complementary to *abl* exon 2 and at least one catalytic sequence capable of cleaving *abl* or *bcr* sequences. The ribozymes further comprise at least one region complementary to *bcr* exon 2. In addition, ribozymes are provided which are capable of cleaving at a distance from at

35 least one region of complementarity to the substrate mRNA.

The present invention also provides ribozymes having an anchor sequence for anchoring the ribozyme to a



region of the substrate mRNA that may be noncontiguous with the region of substrate mRNA complementary to a leg of the ribozyme. Certain preferred embodiments provide ribozymes capable of cleaving a target mRNA in which the catalytic recognition sequence is located at a distance from the region in the target mRNA that is complementary to the anchor of the ribozyme. The ribozymes of the present invention are useful, for example, in the treatment of diseases involving translocations, such as CML, ALL and follicular lymphoma. The ribozymes of the present invention are also useful, for example, to cleave mRNAs associated with diseases in which the mRNA has an area causing a steric obstacle to binding of the ribozyme to the substrate near the catalytic recognition site.

Methods are provided for treating vertebrates with chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) in which the L6 mRNA or both the L6 and K28 mRNAs are expressed. These methods comprise administering at least one oligonucleotide therapeutic, such as a ribozyme or an antisense oligonucleotide, capable of decreasing expression of L6 mRNA or both the L6 and K28 mRNAs.

Combination treatments are preferred embodiments wherein when both the L6 mRNA and the K28 mRNA are targeted. For example, an L6-specific ribozyme is used in conjunction with a ribozyme specific for the K28 transcript in those patients who express both types of mRNAs. Combination therapy is especially important to those patients having the K28 translocation who express both the L6 and K28 mRNAs either simultaneously or consecutively during the course of the disease. Treatment with a therapeutic agent specific for either the L6 or the K28 mRNA would likely be ineffective in these patients, unless the ribozyme was capable of cleaving both.

Unexpectedly, it was discovered that the ribozymes according to the invention, directed against the L6 mRNAs, also cleaved the K28 substrate RNAs, but not the substrates representing native *abl* and *bcr*. This finding was

particularly surprising because the K28 translocation contains a 75 base-pair exon which is not present in the L6 translocation. The ribozymes according to the invention were able to nucleate and cleave the K28 substrate without sacrificing specificity. This is, to the inventors' knowledge, the first report of a single ribozyme specific for two aberrant translocation products. Thus, combination therapy can be effected by the administration of a single ribozyme.

10 Further, combination treatments are provided for those patients also expressing c-myc using oligonucleotide therapeutics (such as antisense oligonucleotides or ribozymes) specific for c-myc RNA along with oligonucleotide therapeutics specific for at least one of the K28 and L6  
15 mRNAs.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the K28 and L6 translocations.

Figure 2 depicts certain preferred embodiments of the L6(1) ribozymes of the present invention described in  
20 Example 1.

Figure 3 illustrates certain preferred embodiments of the L6(2) ribozymes of the present invention described in Example 2.

Figures 4 a-c depict the time course of the  
25 cleavage of the *bcr-abl* substrate by ribozymes L6(1)<sub>31</sub>, L6(1)<sub>21</sub>, and L6(1)<sub>11</sub>, respectively.

Figures 5 a and b depict the specificity of the ribozymes. Native *abl* and *bcr* substrates were not cleaved.

Figures 6 a and b illustrate the proposed  
30 secondary structure in the substrate RNAs.

Figures 7 a-c depict the reaction kinetics for ribozymes L6(1)<sub>11</sub> and L6(1)<sub>21</sub>.

#### DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the present invention provides  
35 ribozymes having an anchor sequence for anchoring the

- 9 -

ribozyme to a region of the substrate mRNA that may be noncontiguous with the region of substrate mRNA complementary to a leg of the ribozyme. Ribozymes capable of cleaving a sequence that is present at a distance from the region of nucleation are provided as embodiments of the invention. Certain preferred embodiments include ribozymes capable of cleaving an L6 mRNA. The invention also furnishes methods of treating a vertebrate suspected of having CML or ALL in which the vertebrate's hematopoietic cells are believed to express L6 mRNA. Methods of treatment comprise administering to the vertebrate at least one oligonucleotide therapeutic targeted to the L6 mRNA. Other methods also target c-myc in conjunction with at least one of L6 and K28 mRNAs.

One embodiment of the present invention involves ribozymes effective for cleaving the L6 mRNA within either *abl* or *bcr* sequences and preferably within *abl*, which sequences are present in both the K28 and the L6 mRNAs.

Ribozymes are catalytic RNAs which are capable of self-cleavage or cleavage of another RNA molecule. Several different types of ribozymes, such as hammerhead, hairpin, Tetrahymena group I intron, axhead, and RNase P are known in the art. (S. Edgington, *Biotechnology* 1992 10, 256-262.) Hammerhead ribozymes have a catalytic site which has been mapped to a core of less than 40 nucleotides. Several ribozymes in plant viroids and satellite RNAs share a common secondary structure and certain conserved nucleotides. Although these ribozymes naturally serve as their own substrate, the enzyme domain can be targeted to another RNA substrate through base-pairing with sequences flanking the conserved cleavage site. This ability to custom design ribozymes has allowed them to be used for sequence-specific RNA cleavage. (G. Paolella et al., *EMBO* 1992, 1913-1919.) It will therefore be within the scope of one skilled in the art to use different catalytic sequences from various types of ribozymes, such as the hammerhead catalytic sequence and design them in the manner disclosed herein.

- 10 -

Ribozymes may also be designed to enhance the rate of the cleavage reaction. For example, Goodchild and Kohli, *Archives of Biochemistry and Biophysics* 1991, 284, 386-391 teach the reduction of complementary nucleotides capable of  
5 base pairing with the substrate from 20 to 12. Additionally, mismatches may be introduced to allow recognition to be spread over a larger number of bases while preventing binding that is too strong. For a discussion of kinetics, see for example, Herschlag, *Proc. Natl. Acad. Sci.*  
10 1991, 88, 6921-6925. Certain preferred embodiments of the invention include sufficient complementarity to specifically target the *abl-bcr* fusion transcript while maintaining efficiency of the cleavage reaction.

An example of an assay for determining whether the  
15 ribozyme is capable of cleaving the targeted mRNA is as follows. An RNA substrate, such as the *bcr-abl* substrate, is incubated with the ribozyme to be tested under appropriate conditions. The reaction products are then tested using, for example, gel electrophoresis. A  
20 detectable cleavage of the substrate mRNA represents a positive result indicating the ribozyme is capable of cleaving the target mRNA.

A preferred embodiment of the invention provides ribozymes comprising at least one region complementary to  
25 *abl*, and a region complementary to *bcr*. Further preferred embodiments include a spacer region of non-complementarity between a region of complementarity (such as an anchor) and a second region of complementarity (such as a leg). Preferably, the ribozyme catalytic motif is the hammerhead  
30 catalytic core sequence, and more preferably, the catalytic sequence is

5' CUGAUGAGUCCGUGAGGACGAA 3' (SEQ ID NO: 11).

Preferred embodiments have two legs having about 2 to about 30 nucleotides, and preferably about 15  
35 nucleotides, complementary to *abl* sequences. The lengths of the legs do not have to be the same. Preferred embodiments also include about 2 to about 500, preferably about 11,

- 11 -

nucleotides complementary to the *bcr* sequences, and representing an anchor. The ribozymes of the present invention are capable of cleaving L6 and/or K28 mRNAs.

Further preferred embodiments include about 1 to  
5 about 3,000, preferably about 1 to about 1,000, more preferably about 1 to about 100, and most preferably about 13, nucleotides of non-complementary spacer sequence between the complementary regions, such as the region complementary to *abl* and the region complementary to *bcr*. Certain  
10 preferred embodiments cleave the *bcr-abl* fusion mRNA at the GUA site within the *abl* region located 19 nucleotides 3' of the *bcr-abl* junction. These are designated as the L6(1) class of ribozymes in the discussion which follows. Other preferred embodiments target the CUU site within the *abl*  
15 region located 7 nucleotides 3' of the *bcr-abl* junction, and these are designated as the L6(2) class. Given the present disclosure, one skilled in the art would recognize these and other sequences of potential cleavage sites, depending upon the targeted sequence and the type of catalytic core motif  
20 used in the ribozyme.

The L6(1) class of ribozymes were designed to cleave at the GUA motif located 19 nucleotides (nts) 3' of the *bcr-abl* junction (Figure 2). These ribozymes contain sequences that are complementary to *abl* sequences present on  
25 either side of the GUA triplet and in addition contain an anchor sequence that is complementary to sequences in *bcr* exon 2 which are non-contiguous with the sequences complementary to *abl*. Figure 2, and subsequent figures, is a simplified representation of the associations immediately  
30 prior to cleavage for illustration purposes. As is evident from the predicted secondary structure depicted in Figures 6a and 6b, the substrate immediately 3' of the junction is not readily available for complementary base-pairing.

Secondary structure predictions for substrate RNAs  
35 were generated using the Zucker and Steigler algorithm for RNA folding. Although the complete nucleotide sequence of the synthetic substrate molecules was analyzed, only a

- 12 -

portion of the folded structure is presented in the figures. The anchor complement and substrate cleavage sites are indicated. Designations #1 and #2 indicate the two ribozyme cleavage sites CUU and GUA, respectively. The *bcr-abl* junction in the L6 *bcr-abl* substrate is indicated by the vertical line between AAG/AAG and the numbers in parentheses indicate the first and last nucleotide in the presented structure. Figure 6a represents normal *abl* substrate; nt 1-87 are derived from *abl* exons 1a and 2. Figure 6b represents the L6 *bcr-abl* substrate; nt 1-14 are derived from the Bluescript polylinker sequence, nt 15-72 are derived from *bcr* exon 2, and nt 73-232 are derived from *abl* exon 2.

The anchor was inserted in order to favor hybridization of the ribozyme to RNAs containing *bcr* sequences, thus discouraging the ribozyme from cleaving normal *abl* mRNAs. The anchor may also function to sequester the ribozyme in the vicinity of the cleavage site, a region which may be buried in secondary structure. Anchors of various lengths were tested. Preferred embodiments of the L6(1) ribozymes includes the following ribozymes:

5' GUCAGAU GCCUGAUGAGUCCGUGAGGACGAAACUGGCAAGAACCCAAAAACUCCUUA  
UU GAUGGUCAGCGGAAUUCUGUG 3' L6(1)<sub>11</sub> (SEQ ID NO: 2) and  
5' GUCAGAU GCCUGAUGAGUCCGUGAGGACGAAACUGGCAAGAACCCAAAAACUCCUUA  
UU GAUGGUCAGCG 3' L6(1)<sub>21</sub> (SEQ ID NO: 15) and  
5' GUCAGAU GCCUGAUGAGUCCGUGAGGACGAAACUGGCAA  
GAACCCAAAAACUCCUUAUUG 3' L6(1)<sub>11</sub> (SEQ. ID NO: 14)

The L6(2) class of ribozymes were designed to cut at the CUU motif located seven nucleotides 3' of the *bcr-abl* junction. The region that is complementary to *bcr* exon 2, is preferably about 2 to about 500, more preferably about 5 to about 100, and most preferably about 5 nucleotides. The catalytic core sequence is preferably the hammerhead catalytic core motif. In certain preferred embodiments, each of the two legs is about 4 to about 15, preferably about 7 nucleotides in length.

- 13 -

Preferred embodiments of the L6(2) ribozymes include the following ribozymes:

5'GCCGCUGCUGAUGAGUCCGUGAGGACGAAAGGGCUUCUCC 3' (SEQ ID NO: 3); 5'GCCGCUGCUGAUGAGUCCGUGAGGACGAAAGGGCCACUCC 3' (SEQ ID NO: 4).

The complementary sequences can be varied and are different in each of the ribozymes above. The first ribozyme (SEQ ID NO: 3) maintains perfect complementary to *abl* exon 2 across the region located 3' of the catalytic sequence, while the second ribozyme listed above contained 2 mismatches to the *abl* exon 2 sequence. Hybridization of ribozymes containing mismatches to the *abl* exon 2 sequence to an RNA molecule would presumably be dependent on both the *bcr* and *abl* complementary sequence. The preferred number of mismatches with *abl* sequences are those that allow greater efficiency of cleavage while retaining specificity.

The majority of hammerhead ribozymes described in the literature comprise a hammerhead sequence, flanked by "legs," which are sequences complementary to the target sequence and which flank the catalytic site. The complementarity serves to guide the ribozyme to the desired site of cleavage and is, therefore, generally responsible for the specificity of ribozyme cleavage. However, in designing such ribozymes, it is presumed that the regions on the target sequence immediately flanking the catalytic site are "open" for the initial binding, i.e., the nucleation critical to ribozyme function.

The present invention provides, for example, ribozymes capable of cleaving a sequence that is present at a distance from the "open" region of complementarity, such as in CML, ALL and follicular lymphoma where chromosome breakpoints may occur at various locations. These ribozymes include sufficient complementarity on one side of the cleavage site to allow stable hybridization, and similarly sufficient complementarity on the other side of the cleavage site. These regions of complementarity can be attached to a spacer consisting of nucleotides or other molecules, such as

- 14 -

polyethylene glycol, that do not substantially hybridize with the sequences of the substrate located between the complementary nucleotide sequences of the ribozyme. The phrase "does not substantially hybridize" signifies that there may be some complementarity present in the spacer sequence so long as it does not hybridize well enough to impede the efficiency of the cleavage reaction.

This region of unmatched nucleotides can serve as a link between the complementary regions of the legs and anchor located at a distance from one another. Thus, these ribozymes would allow cleavage at a distance from one of the complementary regions. In certain preferred embodiments, a longer region of complementarity distant from the cleavage site serves to anchor the ribozyme. The specificity and rate of cleavage of the ribozyme may be modified by changing the extent of base pairing present in any one region of complementarity to the target.

The term "leg" is defined as a region of complementarity which is capable of binding to a complementary region in the substrate mRNA contiguous with the cleavage site. In a preferred embodiment, the region of complementarity on the leg is contiguous with the catalytic sequence of the ribozyme. It is understood that the phrase "capable of binding" encompasses ribozymes with nucleotides that do not precisely match the target mRNA so long as the leg is capable of detectably binding the target region in the substrate. Thus, complementarity may include mismatches so long as the region remains capable of binding the targeted area. The legs of a ribozyme generally function in nucleation and base pair with the substrate thereby allowing the precise positioning of the catalytic domain adjacent to a site for cleavage. Haseloff, et al., *Nature* 1988, 334: 585-591.

The term "anchor" encompasses a region of complementarity with the substrate mRNA that may be either contiguous with one of the legs (without a spacer in the ribozyme) or noncontiguous with one of the legs (with a



- 15 -

spacer in the ribozyme). The anchor is characterized by being capable of binding to a region of the substrate mRNA which can be noncontiguous with the regions of the substrate mRNA complementary to the legs and by effecting nucleation  
5 when secondary structure prevents the legs from doing so and/or helping to improve specificity of the legs when the target sequence is in a region distant from the junction in a chimeric RNA. The length of the noncontiguous area on the substrate can be as short as 1 nucleotide, but is preferably  
10 at least about 3 nucleotides.

An advantage conferred by ribozymes with an anchor sequence includes, for example, the ability to cleave an aberrant fusion mRNA in which the catalytic recognition sequence in the substrate mRNA is located at a distance from  
15 the junction in the substrate fusion mRNA. Fusion RNAs involve a translocation of two chromosomes that places a gene on one chromosome in juxtaposition with a gene on another chromosome. Upon transcription, the translocation thus generates a fusion mRNA. When the catalytic  
20 recognition site is near the junction, ribozymes having a leg complementary to each RNA species immediately on either side of the breakpoint can be utilized to target the fusion RNA; presumably, without also cleaving the two native RNA species which it represents. Naturally, as the catalytic  
25 recognition site moves farther away from the junction, the possibility that the ribozyme will also cleave the native RNAs increases. As is evident from Figure 1, all of the cleavage sites on the L6 fusion product are greater than or equal to 7 nucleotides away from the junction.

30 A ribozyme according to the present invention affords greater specificity for the substrate RNA when the catalytic recognition site is at a distance from the junction. It also provides a mechanism for overcoming obstacles near the catalytic site, such as secondary  
35 structure, which inhibit ribozyme cleavage. A general method for preparing such ribozymes is disclosed herein.

- 16 -

The first step in the method of making a ribozyme, when using, for example, the hammerhead catalytic core, is to identify an XUX site (X being any one of the four nucleotides) in the substrate mRNA. The second step is to  
5 create the legs of the ribozyme. With a known gene sequence, the ribozyme can be designed so that the legs of the ribozyme are complementary to either side of the XUX site in the substrate mRNA. Preferably, the ribozyme will be designed so that it does not substantially cleave normal  
10 mRNA corresponding to the sequences present in the fusion mRNA. The third step involves the creation of an anchor sequence. The anchor sequence can be targeted against a region in a fusion mRNA distant to the catalytic recognition sequence such that the anchor is complementary to a region  
15 in a different RNA species than the one with the catalytic target recognition site. A spacer region may optionally be included in the ribozyme. When inhibiting secondary structure is present, the anchor can be designed to be complementary to a region on the substrate RNA immediately  
20 5', 3', and/or even within, this structure.

The anchor allows the ribozyme to recognize and bind to the sequences complementary to the anchor, such as the region of the mRNA corresponding to the translocation, even though the catalytic site is distant from the  
25 translocation junction. Even if the size of the ribozyme does not correspond to the size of the substrate mRNA that spans the area between the translocation and the catalytic site, any non-complementary portion of the substrate mRNA may form a localized secondary structure, such as a loop,  
30 thus permitting the ribozyme to bind to the noncontiguous sequences.

It will be understood that the ribozyme can be designed to cleave any portion of the substrate mRNA; the targeted region need not be located near the translocation  
35 junction. Similarly, the anchor sequence need not be targeted to the translocation junction. Our results indicated that the L6 ribozymes cleaved both the L6 and K28

messages, and that this cleavage was specific for the aberrant messages only. It will also be understood that a single ribozyme can be effective for many different translocations resulting in the same fusion mRNA.

5 Another example of an advantage conferred by a ribozyme with an anchor sequence is the ability to avoid steric hindrance located near the catalytic recognition sequence in the substrate mRNA, in addition to that due to secondary structure. An example of another situation  
10 creating steric hindrance includes the binding of proteins to the substrate mRNA. The presence of secondary structure can be determined, for example, using computer programs such as PC Gene (Intelligenetics, Mountain View, CA), and/or by chemical or enzymatic means.

15 An advantage conferred by ribozymes with a spacer, for example, is its ability to confer flexibility to the ribozyme, thereby allowing it to rotate in space in order to make contact with the substrate mRNA. A spacer also allows ribozymes to span long distances of the substrate mRNA  
20 without binding to it.

The spacer region may consist of nucleotides or derivatives thereof or non-nucleotide spacers, such as polyalkylene glycol, as well as the non-nucleotide spacers disclosed in Levenson et al., U.S. Patent No. 4,914,210,  
25 which is hereby incorporated by reference. In certain preferred embodiments, the spacer consists of polyethylene glycol. In other preferred embodiments, the spacer region has 1 to about 3000 nucleotides or derivatives thereof. More preferred embodiments have at least about 13  
30 nucleotides. The phrase "chemical spacer region" means a spacer region having a chemical spacer such as, for example, those chemicals disclosed in U.S. Patent No. 4,914,210. A specific example is polyalkylene glycol, and more preferably, polyethylene glycol. One skilled in the art can  
35 determine whether such a chemical is equivalent in size to 1 to 1,000 nucleotides.

- 18 -

It will be understood that, once armed with the present invention, one skilled in the art will be able to create ribozymes with multiple anchor sequences as well as ribozymes with multiple spacers and combinations of anchors and spacers. In preferred embodiments, the ribozymes have between 1 and about 100 anchor sequences and more preferably between 1 and about 10. Likewise, in preferred embodiments, the ribozymes have between about 1 and 100 spacer regions, and more preferably between 1 and about 10.

10 In preferred embodiments, each leg of the ribozyme has about 2 to about 15 nucleotides, and preferably about 7 nucleotides. The anchor sequence preferably has about 2 to about 500 nucleotides and more preferably about 5 to about 100 nucleotides. The optional spacer region preferably  
15 spans about 1 to 3000 nucleotides of the substrate mRNA, more preferably about 1 to 1000 nucleotides, and most preferably about 10 to about 100 nucleotides.

Once armed with the present disclosure, one skilled in the art would be able to make modifications in  
20 the design of these ribozymes in order to increase the efficiency and/or specificity of the cleavage reaction. These modifications include, for example, in the case of CML, increasing the size of the region which is complementary to *bcr* exon 2 and/or decreasing the amount of  
25 complementarity to *abl* exon 2.

In certain preferred embodiments, the ribozymes include multiple catalytic units. Given the present disclosure, one skilled in the art is capable of making ribozymes having multiple catalytic units which are capable  
30 of cleaving the substrate mRNA, such as the K28 mRNA and/or L6 mRNA. Such ribozymes may include spacer regions between the catalytic units in addition to regions of complementarity with the substrate mRNA. The catalytic units themselves may cleave, for example, *abl* and/or *bcr*  
35 sequences.

Examples of ribozymes with a spacer region joining the anchor to one of the legs include ribozyme L6(1)<sub>31</sub> (SEQ

- 19 -

ID NO: 2) in Example 1 and ribozymes L6(2)<sub>0</sub> and L6(2)<sub>2</sub> in Example 2 (SEQ ID NO: 4 and 5). Preferred embodiments include the ribozymes of SEQ ID NO: 14 and SEQ ID NO: 15 which are modifications of SEQ ID NO: 2 having shorter  
5 anchor sequences and which cleave the substrate mRNA more efficiently.

Another example of a ribozyme capable of cleaving a fusion mRNA generated from a translocation is the ribozyme of SEQ ID NO: 13. This ribozyme is targeted against a  
10 fusion mRNA involved in ALL and may be used in the treatment of ALL. A 9;22 chromosomal translocation is associated with ALL. The breakpoints on chromosome 9 lie upstream of *abl* exon 2. Transcription through this region yields a fusion mRNA in which the first *bcr* exon is adjacent to *abl* exon 2.  
15 The anchor of this ribozyme is complementary to *bcr* exon 1, and the remainder of the ribozyme corresponds to the spacer region, legs and catalytic sequence of SEQ ID NO: 2.

Given the present disclosure, one skilled in the art would also be able to create a ribozyme targeted  
20 against, for example, follicular lymphoma and other diseases involving translocations.

It will also be understood that the ribozymes may be modified; for example, by using 2'-O-alkyl- and 2'-O-allyl-ribonucleotide analogues. Paoletti et al., *EMBO J.*  
25 1992, 11, 1913-1919. Such modifications are included within the term "derivatives." Additionally, mixed deoxyribonucleotides and ribonucleotides may be used. Perreault et al., *Nature* 1990, 344, 565-567.

Further, known catalytic sequences may be altered.  
30 For example, the consensus sequence in the core catalytic region of the hammerhead ribozyme may be changed, e.g., according to Ruffner et al., *Biochemistry* 1990, 29, 10695-10702.

The present invention also provides methods for  
35 treating vertebrates suspected of having CML or ALL wherein it is believed that the vertebrate's hematopoietic cells express L6 mRNA. Preferred embodiments involve using

- 20 -

oligonucleotide therapeutics capable of decreasing the expression of L6 mRNA or both the L6 and K28 mRNAs. The term "oligonucleotide therapeutics" includes both ribozymes and antisense RNA. In certain preferred embodiments, the  
5 oligonucleotide therapeutic comprises a ribozyme capable of cleaving L6 mRNA. In another preferred embodiment, the oligonucleotide therapeutic comprises an antisense oligonucleotide capable of binding the K28 and an antisense oligonucleotide capable of binding the L6 mRNA. A further  
10 preferred embodiment provides a mixture of ribozymes and antisense oligonucleotides specific for the K28 and L6 mRNAs. In another preferred embodiment, the "oligonucleotide therapeutic" comprises a ribozyme capable of cleaving both L6 and K28.

15 Antisense technology provides a valuable tool that can be used to interfere with the expression of specific genes. Antisense oligonucleotides having sequences that are complementary to sequences of the mRNA of a gene of interest can lead to modifications of the phenotype of the cell.

20 Antisense oligonucleotides which hybridize to at least a portion of the K28 and L6 junctions are contemplated in the methods of the present invention. Thus, molecules which bind competitively to an aberrant transcript are envisioned for therapeutics.

25 While any length antisense oligonucleotide may be utilized, sequences shorter than 15 bases may be less specific in hybridizing to the target and may be more easily destroyed by enzymatic degradation. Hence, oligonucleotides having at least 15 nucleotides are preferred. On the other  
30 hand, the size of the oligonucleotide is limited by its ability to enter the target cell since it is known in the art that large oligonucleotides may be somewhat less effective in interfering with expression because of decreased uptake by the target cell. It will be understood  
35 that interference with expression means that there is a detectable decrease in expression of the protein product

- 21 -

encoded by the *bcr-abl* fusion transcript either *ex vivo* or *in vivo*.

The term "oligonucleotide" as used herein includes both ribonucleotides and deoxyribonucleotides, and includes  
5 molecules which may be long enough to be termed "polynucleotides." Oligodeoxyribonucleotides are preferred since oligoribonucleotides are more susceptible to enzymatic attack by ribonucleotides than deoxyribonucleotides. It will also be understood that the bases, sugars or  
10 internucleotide linkages may be chemically modified by methods known in the art. Modifications may be made, for example, to improve stability and/or lipid solubility. For instance, it is known that enhanced lipid solubility and/or resistance to nuclease digestion results by substituting a  
15 methyl group or sulfur atom for a phosphate oxygen in the internucleotide phosphodiester linkage. The phosphorothioates, in particular, are stable to nuclease cleavage and soluble in lipid.

The ribozymes and the antisense oligonucleotides  
20 of the present invention may be synthesized by any of the known chemical oligonucleotide synthesis methods. See for example, Gait, M.J., ed. (1984), *Oligonucleotide Synthesis* (IRL, Oxford). Both the ribozymes and the antisense oligonucleotides may also be synthesized through recombinant  
25 expression from an appropriate vector.

Preferred embodiments of the present invention involve targeting the L6 mRNA alone or both the L6 mRNA and the K28 mRNA in a combination treatment. In preferred methods for treating CML or ALL, oligonucleotide  
30 therapeutics are used to decrease expression of the targeted mRNAs. The phrase "capable of decreasing expression" signifies a detectable decrease in expression.

Combination therapy is especially important to those patients having the K28 translocation who express both  
35 the L6 and K28 mRNAs either simultaneously or consecutively during the course of the disease. Treatment with a

- 22 -

therapeutic agent specific for either the L6 or the K28 mRNA would most likely be ineffective in these patients.

A preferred method comprises a combination therapy having components specific for both the K28 and L6 mRNAs.

5 Methods of treatment include, for example, a mixture of ribozymes capable of cleaving the K28 and L6 mRNAs.

Another preferred embodiment is a method of treatment of ALL or CML using antisense oligonucleotides containing components capable of binding both the K28 and L6  
10 mRNAs. The phrase "capable of binding" indicates detectable binding in assays known to one skilled in the art, such as a shift in mobility during electrophoresis.

A further preferred embodiment provides a mixture of ribozymes and antisense oligonucleotides specific for the  
15 K28 and L6 mRNAs. These treatments may also be used, for example, in conjunction with conventional therapies such as chemotherapy and irradiation.

A further preferred embodiment provides a single ribozyme capable of cleaving L6 and K28.

20 A further preferred embodiment involves a combination treatment directed against c-myc expression in addition to targeting the K28 and/or L6 mRNAs. The potential role of c-myc in CML is discussed, for example, in Sawyers et al., *Cell* 1992, 70, 901-910. Specifically, myc  
25 affects the transformation ability of *bcr-abl* in vitro and myc has been implicated in some patients with blast crisis of CML. Therefore, certain embodiments of the present invention comprise a combination treatment for those patients also expressing c-myc using a treatment such as  
30 antisense oligonucleotides or ribozymes specific for c-myc RNA along with antisense oligonucleotides and/or ribozymes specific for the K28 and/or L6 mRNAs.

In other preferred embodiments, the ribozyme of SEQ ID NO: 13 may similarly be used in the treatment of ALL.  
35 The substrate mRNA for this ribozyme is provided in SEQ ID NO: 12.



For in vivo use, the antisense oligonucleotides as well as the ribozymes may be combined with a pharmaceutical carrier, such as a suitable liquid vehicle or excipient and an optional auxiliary additive or additives. The liquid  
5 vehicles and excipients are conventional and commercially available. Illustrative thereof are distilled water, physiological saline, aqueous solution of dextrose, and the like.

In addition to administration with conventional  
10 carriers, the antisense oligonucleotides as well as the ribozymes may be administered by a variety of specialized oligonucleotide delivery techniques. For example, oligonucleotides have been successfully encapsulated in unilamellar liposomes. Reconstituted Sendai virus envelopes  
15 have been successfully used to deliver RNA and DNA to cells. Arad et al., *Biochem. Biophys. Acta*. 1986, 859, 88-94 (incorporated herein by reference). Additionally, oligonucleotides may be carried into the cell by exploitation of folate receptor-mediated endocytosis.  
20 Leamon and Low, *Proc. Nat'l. Acad. Sci.* 1991, 88, 5572-5576 (incorporated herein by reference).

It will also be understood that the ribozyme and antisense oligonucleotides may be administered by vector-mediated delivery. Such delivery systems are within the  
25 scope of one skilled in the art once armed with the present disclosure. Preferred methods of gene therapy include, for example, the incorporation of the gene encoding the therapeutic oligonucleotide into a retroviral vector, followed by selection of cells expressing the gene. Using  
30 the retroviral vector, the gene is then transferred into the stem cells of the patient's bone marrow ex vivo. In order to effect repopulation, the patient's own bone marrow is treated, for example, with irradiation, chemotherapy or ablation. The treated bone marrow is then transplanted into  
35 the patient.

For examples of vector-mediated delivery systems, see, Rosenberg, et al., *New Eng. Jour. Med.* 1990, 570-578;

Roux, et al., *Proc. Natl. Acad. Sci.* 1989, 86, 9079-9083;  
DeMonte, et al., *Proc. Natl. Acad. Sci.* 1990, 87, 2941-2945;  
Hantzopoulos, et al., *Proc. Natl. Acad. Sci.* 1989, 86, 3519-  
3523 and Kashani-Sabet, et al., *Antisense Res. and Dev.*

5 1992, 2, 3-15.

For *in vivo* use, the antisense oligonucleotides as well as the ribozymes may be administered in an amount effective to reduce expression of aberrant transcripts. The actual dosage administered may take into account the size  
10 and weight of the patient, whether the nature of the treatment is prophylactic or therapeutic in nature, the age, weight, health and sex of the patient, the route of administration, and other factors.

It is also possible to administer the antisense  
15 oligonucleotides as well as the ribozymes *ex vivo* by isolating white blood cells from peripheral blood, treating them with the oligonucleotides, then returning the cells to the donor's blood. *Ex vivo* techniques have been used in the treatment of cancer patients with interleukin-2 activated  
20 lymphocytes.

The oligonucleotide therapeutics may be administered in amounts effective to kill leukemic cells while maintaining the viability of normal hematologic cells. Such amounts may vary depending on the nature and extent of  
25 the leukemia, the particular oligonucleotide utilized, the relative sensitivity of the leukemia to the oligonucleotide, and other factors.

It will be understood that the treatments of the present invention may be combined with conventional  
30 therapies. It will also be understood that the combination treatments of the present invention may be administered sequentially or simultaneously. Dosage determinations will depend upon the individual and can be determined by one skilled in the art.

## MATERIALS AND METHODS

### Growth and Maintenance of Bacteria

*Escherichia coli* strains HB 101 (Boyer, H.W. and D. Roulland-Dussoix, *J. Mol. Bio.* 1969, 41, 459) and SB 221 (Nakamura, D. and M. Inouye, *Cell* 1979, 18, 1109-1117) were grown in L broth (10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl) at 37°C. For long term storage, bacterial stocks were stored in 75% L broth/25% glycerol at -80°C.

### Plasmid

10 Bluescript II KS + was purchased from Stratagene and maintained in HB 101 which was grown in L broth containing 100 µg/ml ampicillin.

### Construction of Template DNA

Two DNA templates for each ribozyme were synthesized as two complementary oligodeoxynucleotides with *Eco*R1 ends on a Milligen BioSearch 8750 DNA synthesizer, as a sianoeethylphosphoroamidite synthesis (Beaucage, S. and M. Caruthers, *Tetrahedron Lett.* 1981, 22, 1859-1862) and were purified by reverse phase High Pressure Liquid Chromatography (HPLC). Approximately three micrograms of each oligonucleotide was phosphorylated in 1 x linker-kinase buffer (70 mM Tris-Cl, pH 7.6, 1 mM ATP, 10 mM MgCl<sub>2</sub>, 15 mM DTT) containing 50 units of T4 polynucleotide kinase (United States Biochemicals). The reactions were carried out at 25 37°C for 30 minutes.

Complementary oligonucleotides were annealed to each other following phosphorylation by combining reaction mixes and incubating sequentially at the following temperatures for the indicated times: 85°C for 5 minutes; 30 65°C for 15 minutes; 37°C for 15 minutes; room temperature for 15 minutes; and on ice for 15 minutes. The annealed phosphorylated oligonucleotides were ethanol precipitated and resuspended in deionized water (dH<sub>2</sub>O) at a concentration of 75 ng/µl. Once annealed, the double stranded

- 26 -

oligonucleotides were ligated into the *Eco*R1 site of Bluescript II KS +. Ligated DNA was electroporated into BH 101 bacteria using the "gene pulse" (Bio Rad) according to the manufacturer's instruction. Single stranded overhanging  
5 ends complementary to ends generated by *Eco*RI digestion of DNA.

#### Construction and Cloning of Substrate DNAs

The DNA template for the L6 *bcr-abl* substrate RNA was synthesized as an oligodeoxynucleotide having the same  
10 polarity as L6 *bcr-abl* mRNA. This DNA oligonucleotide is comprised of a sequence that maps from a position located 57 nts 5' of the *bcr-abl* junction to a position located 97 nts 3' of the *bcr-abl* junction (Shtivelman, et al., Cell 1986, 47, 277-284; Heister Kamp, et al., Nature 1985, 315, 758-  
15 761.). Double stranded DNA was synthesized by the polymerase chain reaction (PCR) using 5' and 3' primers which have the following sequences:

5' ATTGCGATAGGATTGAATTCAACTCGTGTGTGAACTCCA 3' (SEQ ID NO: 16) and

20 5' AATGCGATAGGATTGAATTCGTCCAGCGAGAAGGTTTTCC 3' (SEQ ID NO: 17)

, respectively. (*Eco*R1 sites are underlined). PCR products were gel purified, *Eco*R1 digested, and then cloned into Bluescript II KS+ as already described.

25 The DNA template for normal *bcr* substrate RNA was synthesized as an oligodeoxynucleotide having the same polarity as *bcr* mRNA. Double stranded DNA was synthesized by PCR using 5' and 3' primers which have the following sequences:

30 5' ATTGCGATAGGATTGAATTCAAGCTTAAGTGTTCAGAAAGCTTCTCCCTGACATCCGT GGAGCTGCA 3' (SEQ ID NO. 18)

5' AATGCGATAGGATTGAATTCGGAGACTCATCATCTTCCTTATTGATGGTCAGCGGAA TGC 3' (SEQ ID NO: 19), respectively. The resulting PCR product maps from position 554 to position 675 of normal *bcr*  
35 cDNA (Lozzio, et al., Blood, 1975, 45, 321-334.

- 27 -

A region of normal *abl* mRNA from K562 cells (Lozzio, et al.) was amplified by reverse transcriptase PCR (Innis, et al., *PCR Protocols*, A Guide to Methods and Applications, 1990). The sequence of the *abl* cDNA primer is: 5'TAGGACTGCTCTCACTTCTCAG 3' (SEQ ID NO: 20). *Abl* specific cDNA was amplified by PCR. The sequences of the 5' and the 3' primers are 5' ATCTGCCTGAAGCTGGTGGGCTGC 3' (SEQ ID NO: 21) and 5' ATGCTTAGAGTGTTATCTCCACT 3' (SEQ ID NO: 22) respectively. The resulting PCR product maps from position 157 to position 340 of normal *abl* cDNA (5).

The normal *bcr* and *abl* PCR products were gel purified, phosphorylated and then blunt ended in the presence of dNTPs and the Klenow fragment of DNA polymerase. The DNA was then cloned into the *Hinc* II site of Bluescript II KS+.

The template for the K28 substrate was provided by Dr. Scott Shore (Temple University, Philadelphia, PA).

#### Preparation of Cloning Vector

Bluescript II KS+ plasmid DNA was digested to completion with either *Hinc* II or *Eco*RI (New England Biolabs) using conditions recommended by the manufacturer. The digested DNA was extracted twice with phenol:chloroform, ethanol precipitated, and then dephosphorylated with Calf Intestinal Phosphatase (Boehringer Mannheim Biochemicals) according to the conditions recommended by the supplier.

#### Ribozyme Cloning

Between 150 ng and 450 ng of annealed oligonucleotide was ligated with *Eco*RI-digested Bluescript II KS+ in 10  $\mu$ l of 1 x ligation buffer (50 mM Tris Cl, pH 7.6, 10 mM MgCl<sub>2</sub>, 1 mM ATP, 10 mM DTT) containing 200 ng of vector DNA and 5  $\mu$ l of T4 DNA ligase (Boehringer Mannheim Biochemicals). Following an overnight incubation at 14°C, the reaction was diluted with 5  $\mu$ l of TE (10 mM Tris-Cl, pH 7.7, 1 mM EDTA) and used immediately or stored at -20°C.

- 28 -

Two microliters of the diluted ligation reactions were electroporated into HB 101 or SB 221 in a Bio-Rad "Gene Pulser" according to the manufacturers instructions.

Transformed bacteria were immediately diluted in 1 ml of SOC  
5 medium (2% [w/v] Bacto Tryptone, 0.5% [w/v] yeast extract, 10 mM NaCl, 10 MgSO<sub>4</sub>-7H<sub>2</sub>O, 20 mM glucose) and incubated at 37°C for one hour. Transformed bacteria were then plated on an L agar plate containing 100 µg/ml ampicillin and incubated at 37°C overnight.

#### 10 Characterization of Clones

Individual transformants were picked and grown in LB medium containing 100 µg/ml ampicillin. Plasmid DNA was harvested from bacterial cultures according to the alkaline lysis protocol (Sambrook, J. Fritsch, E.F. and Maniatis, T.  
15 (eds.), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989). DNA was further purified by lithium chloride precipitation, digestion with RNase A, polyethylene glycol precipitation, extraction with phenol and chloroform and then precipitation  
20 with ethanol (Sambrook, J. Fritsch, E.F. and Maniatis, T. (eds.), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989). DNA was resuspended in dH<sub>2</sub>O at a concentration of 1 µg/l to 2 µg/l.

Aliquots of plasmid DNA were double digested with  
25 PstI (New England Biolabs) and HindIII (New England Biolabs) according to the manufacturer's directions. Products were electrophoresed through 1.5% agarose/TBE (90 mM Tris-borate, 2 mM EDTA) gels at 70 mamps.

#### Sequence Analysis

30 Plasmid inserts of the appropriate size were subjected to DNA sequence analysis using Sequenase (United States Biochemical) and both the M13<sup>-20</sup> and reverse primers according to established protocol (Sambrook, J. Fritsch, E.F. and Maniatis, T. (eds.), *Molecular Cloning, A*  
35 *Laboratory Manual*, Cold Spring Harbor, NY, Cold Spring

- 29 -

Harbor Laboratory, 1989). Products of the sequencing reaction were electrophoresed through a 7% polyacrylamide/urea gel (Sambrook, J. Fritsch, E.F. and Maniatis, T. (eds.), *Molecular Cloning, A Laboratory Manual*,  
5 Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989).

#### Template Preparation for T7 and T3 Transcription

Plasmid DNAs were digested to completion with either *HindIII*, *PstI*, *BamHI*, or *XhoI* (New England Biolabs)  
10 according to the manufacturer's directions. Digested DNA was ethanol precipitated and resuspended in 200  $\mu$ l of 1 x Proteinase K buffer (10 mM Tris-Cl, pH 8.0, 5 mM EDTA, 0.5% SDS) containing 1  $\mu$ l of a freshly made Proteinase K solution (10 mg/ml) (Sigma).

15 The reactions were incubated at 37°C for 30 minutes and then extracted twice with phenol:chloroform. DNA was ethanol precipitated and resuspended in RNase free H<sub>2</sub>O (Sambrook, J. Fritsch, E.F. and Maniatis, T. (eds.), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor,  
20 NY, Cold Spring Harbor Laboratory, 1989) at a concentration of 500 ng/ $\mu$ l.

#### In Vitro Transcription

The substrate and ribozyme RNAs were transcribed from the Bluescript II Ks + template using either T3 RNA  
25 polymerase (Promega) or T7 RNA polymerase (Promega) according to instructions provided by the manufacturer. Following transcription, the DNA templates were removed from the reaction by adding RNase free DNase (Worthington Biochemical) at 5  $\mu$ g/ $\mu$ l or 2 units per  $\mu$ g) of DNA template  
30 and incubating at 37°C for 30 minutes. RNA was concentrated by ethanol precipitation and then subjected to proteinase K digestion, and resuspended in RNase Free H<sub>2</sub>O. Substrate RNAs used as tracers in ribozyme cleavage experiments were radiolabelled during T7 or T3 transcription with [ $\alpha^{32}$ P] CTP

- 30 -

(Amersham) according to the manufacturers recommended procedure.

### Ribozyme Assays

Ten picomoles of both ribozyme and substrate RNAs were incubated in 10  $\mu$ l of 1 x ribozyme reaction buffer (50 mM Tris-Cl, pH 7.5, 10 mM  $MgCl_2$ ) containing either 10 mM vanadylribonucleoside complexes or 40 units of RNasin (Promega). Reactions were incubated at 37°C for 13-15 hours and terminated by the addition of 10  $\mu$ l formamide loading buffer (80% formamide, 10 mM EDTA, 1 mg/ml xylene cyanol FF, 1 mg/ml bromophenol blue). Samples were denatured at 95°C for two minutes prior to denaturing polyacrylamide gel electrophoresis. Alternatively, ten pmole of both ribozyme and substrate RNAs were incubated in 10  $\mu$ l of ribozyme reaction buffer (50 mM Tris-Cl, pH 7.5, 10 mM  $MgCl_2$ ) containing 50,000 cpm of radiolabelled substrate RNA (specific activity  $[5 \times 10^8 \text{ cpm}/\mu\text{g}]$ ) as tracer. Reactions were incubated at 37°C for up to 10 hours and terminated by freezing on dry ice. Samples were subjected to denaturing polyacrylamide gel electrophoresis on 5% polyacrylamide gels (Boyer, P.D., 1970, *The Enzymes*, Student Ed., Academic Press, Inc., New York, NY.) ). Gels were dried and subsequently analyzed with a PhosphorImager (Molecular Dynamics) according to the manufacturer's directions.

### 25 Gel Shift Analysis

Fifty pmole of ribozyme and 10 pmole of substrate were incubated in 10  $\mu$ l of ribozyme reaction buffer containing 50,000 cpm of radiolabelled substrate RNA (specific activity  $[5 \times 10^8 \text{ cpm}/\mu\text{g}]$ ) at 37°C for 2.5 hours. Products were analyzed by native gel electrophoresis (non-denaturing) on a 6% polyacrylamide gel in 1 x TBM buffer (90 mM Tris-borate, 10 mM  $MgCl_2$ ). Gels were dried and subsequently analyzed with a PhosphorImager (Molecular Dynamics). All ribozymes shifted the substrate *bcr-abl* bands. Two conformational species of *bcr-abl* were detected.



- 31 -

**Kinetic Analysis**

Ribozyme reactions were carried out as described above but in the presence of substrate excess. The ribozyme concentration was held constant at 0.5  $\mu$ M. The various  
 5 substrate to ribozyme ratios used are described below. Reactions were terminated at various times and the products subjected to denaturing gel electrophoresis. Gels were dried and subsequently analyzed with a PhosphorImager.

**RNA Folding**

10 Secondary structures were predicted for ribozymes and substrate RNAs using the programs of Zucker and Steigler, on PC Gene (Intelligenetics) and MacDNASIS Pro (Hitachi).

**Cells**

15 K562 cells (Blood, 1975, 45, 321-334) were obtained from the American Type Culture Collection (ATCC #CCL 243) and were cultured in complete minimal essential medium (JRH Biosciences) supplemented with 10% Fetal Bovine Serum (Gibco-BRL).

**20 Example 1**

The L6(1) Ribozymes and their substrate are listed below; the recognition sequence in the substrate cleaved by this ribozyme is indicated in bold, the spacer sequence in the ribozyme is underlined, the junction is symbolized by |  
 25 and the catalytic core is indicated by brackets.

5' CACAGCAUUCGCGUGACCAUCAUAAGGAAG | AAGCCCUUCAGCGGCCAGUAGCAUCU  
 GACUU 3' (SEQ ID NO: 1)

3' GUGUCGUAAGGCGACUGGUAGUUAUUCUUC | AAAAACCCAAGAACGGUCA  
 [AAGCAGGAGUGCCUGAGUAGUC] CGUAGACUG 5' L6(1)<sub>31</sub> (SEQ ID NO:2)

30 3' GUUAUUCUUC | AAAAACCCAAGAACGGUCA  
 [AAGCAGGAGUGCCUGAGUAGUC] CGUAGACUG 5' L6(1)<sub>11</sub> (SEQ ID NO:14)

3' GCGACUGGUAGUUAUUCUUC | AAAAACCCAAGAACGGUCA  
 [AAGCAGGAGUGCCUGAGUAGUC] CGUAGACUG 5' L6(1)<sub>21</sub> (SEQ ID NO:15)

- 32 -

Cleavage of the L6 substrate *in vitro* using L6(1)<sub>31</sub> resulted in the production of the expected cleavage products described above. Fifteen to forty percent of the substrate was cleaved using equimolar amounts of ribozyme and  
5 substrate. The remainder of the substrate migrated as an uncleaved species of approximately 230 bp. Increasing the ratio of ribozyme:template approximately 3-fold resulted in a slight increase in the amount of cleavage product generated. This ribozyme is apparently specific for the L6  
10 substrate since no cleavage of the K28 substrate was detected.

The L6(1) class of hammerhead ribozymes, depicted in Figure 2, sequences listed above, comprised anchors located at the 3' end of the ribozyme complementary to the  
15 region of *bcr* exon 2 of 31, 21, or 11 nucleotides in length. They were connected to the 5' portion of the ribozyme by means of a 13 nucleotide spacer sequence. This spacer bears no complementarity to either *abl* or *bcr* sequences. The hammerhead catalytic core, located near the 5' end of the  
20 ribozyme, lies within a 15 nt sequence that is complementary to *abl* exon 2. A control ribozyme which lacks an anchor sequence, but is otherwise homologous to the anchored ribozymes, was also constructed and tested (SEQ ID NO: 23).

These ribozymes have been designed to cleave the  
25 L6 *bcr-abl* mRNA at the GUA triplet located 19 nts 3' of the *bcr-abl* junction. Cleavage at this site in the synthetic substrate generates two fragments which are 143 nt and 85 nts in length (consisting of 77 or 73 nucleotides of substrate and 66 or 12 nucleotides of polylinker,  
30 respectively). Each of the ribozymes was able to cleave the L6 substrate into the expected cleavage products, and the amount of substrate cleaved by each ribozyme, was, in general, inversely related to the length of the anchor sequence. Figures 4 a-c depict the time course of the  
35 cleavage products for the L6(1)<sup>31</sup>, L6(1)<sup>21</sup>, and L6(1)<sup>11</sup> ribozymes, respectively. Substrate bands are indicated with an "S". Product bands are indicated with a "P". The 21 nt

anchor ribozyme, however, demonstrated more activity than the 11 nt anchor ribozyme at the earlier time points. The ribozyme not having an anchor also correctly cleaved the L6 substrate. Cleavage was less efficient than with an anchor and less product formation was observed. No cleavage products were detected in the absence of ribozyme.

None of the anchor sequences prevented the correct cleavage of the L6 substrate. Kinetic analysis, however, indicated that product release, the rate limiting step in the cleavage reactions, was slower in reactions catalyzed by ribozymes with longer anchors. The initial burst rate was similar for both the 11 nt anchored and the 21 nt anchored ribozyme when reactions were carried out under conditions of substrate excess. These rates are slower than the rates measured for other ribozymes (*Proc. Natl. Acad. Sci. USA* 1990, 87, 1668-1672; *Biochemistry*, 1992, 31, 12042-12054.) However, the rates of the anchored ribozymes were measured in reactions using a large substrate RNA molecule while the rates reported for the other ribozymes were determined in reactions using a small oligoribonucleotide substrate. The 21 nt anchored ribozyme was more active than the 11 nt anchored ribozyme when reactions were carried out under conditions of ribozyme excess. Under these conditions, the rate of cleavage by each ribozyme was slower than the rate measured in reactions where substrate was in excess indicating that the ribozymes may undergo a substrate induced conformational change (ie. see *Nucleic Acids Res.* 1990, 18, 1103-1108. However, for therapeutic purposes, it is advantageous that the ribozymes are more efficient at substrate excess. The 21 nt anchored ribozyme has a slower product dissociation rate than does the 11 nt anchored ribozyme, however, and the net result is that the 11 nt anchored ribozyme is more efficient over an extended reaction time.

The ribozymes are specific for *bcr-abl* mRNA. Secondary structure predictions for substrate RNAs were generated using the Zucker and Steiger algorithm for RNA

folding. Secondary structure predictions for normal *abl* RNA suggest that the sequences flanking the cleavage site may not be accessible for ribozyme binding (Figure 6a). This was confirmed experimentally utilizing an *in vitro* binding assay. We predicted that the ribozymes would cleave the normal *abl* substrate if the secondary structure of the substrate was first melted. Experiments were therefore carried out in which the substrate was first denatured and then renatured in the presence of ribozyme. Under these conditions, between 15 and 20% of the normal *abl* substrate was cleaved by the 11 nt anchored ribozyme. This result, together with the gel shift data, support the interpretation that the normal *abl* substrate is folded in a way that occludes ribozyme nucleation. It is therefore likely that the anchored ribozymes failed to cleave normal *abl* RNA because it is inaccessible for ribozyme binding.

Secondary structure predictions for the L6 *bcr-abl* substrate suggest that the sequences flanking the ribozyme cleavage site are also inaccessible for ribozyme binding but that most of the region complementary to the ribozyme anchor is available for anchor hybridization (Figure 6b). Although these predictions were generated for a substrate RNA that contains a vector derived polylinker sequence, predictions made for the native substrate RNA indicated that most of the anchor complement is available in this molecule as well. According to our model, the function of the ribozyme anchor is to tether the ribozyme to an accessible substrate sequence thereby sequestering the molecule in the vicinity of the substrate cleavage site. This would allow the ribozyme to cleave the substrate whenever the cleavage site and flanking sequences become available due to temporary transitions in secondary structure. These alternate secondary structures may actually be fostered and/or stabilized by further ribozyme interactions.

Although we have used a chimeric RNA to demonstrate the utility of a ribozyme anchor in overcoming an obstruction caused by the secondary structure around a

- 35 -

cleavage site, an anchor could potentially be used to target ribozymes to occluded sites in any RNA molecule.

The optimal length of an anchor is probably dependant upon the anchor sequence and the secondary structure. The presence of some form of anchor is clearly important as inefficient cleavage was observed with the anchor-minus ribozyme. The anchors we tested in this example were attached to the ribozyme via a 13 nucleotide spacer. Anchors might also be connected via a chemical spacer or simply linked directly to the ribozyme. The presence of a spacer may be sterically important in cases in which a ribozyme is tethered at a position distant from the cleavage site.

Tests revealed that, unexpectedly, L6(1)<sub>11</sub> also cleaved the K28 substrate. This was demonstrated by incubating L6(1)<sub>11</sub> with the K28 substrate. The reaction products were electrophoresed through a denaturing 5 % polyacrylamide gel and visualized with ethidium bromide. Thus, while not cleaving native *abl* or *bcr*, L6(1)<sub>11</sub> cleaved both L6 and K28. Considering the potential variation in the K28 transcript during the course of disease, L6(1)<sub>11</sub> could be a valuable therapeutic.

#### Example 2

The L6(2) ribozymes (L6(2)<sub>0-4</sub>) are depicted in Figure 3. Their sequences and substrate are listed below; the recognition sequence in the substrate cleaved by these ribozymes is indicated in bold, mismatched sequences in the ribozymes are underlined, the junction is symbolized by | and the catalytic core is indicated by brackets.

5' CACAGCAUUCGCGUGACCAUCAUAAGGAAG | AAGCCCUUCAGCGGCCAGUAGCAUCU  
GACUU 3' (SEQ ID NO: 1)

3' CCUUC | UUCGGGA [AAGCAGGAGUGCCUGAGUAGUC] GUCGCCG 5'

L6(2)<sub>0</sub> (SEQ ID NO: 3)

3' CCUUC | ACCGGGA [AAGCAGGAGUGCCUGAGUAGUC] GUCGCCG 5'

L6(2)<sub>2</sub> (SEQ ID NO: 4)

3' CCUUC | ACAGGGA [AAGCAGGAGUGCCUGAGUAGUC] GUCGCCG 5'

- 36 -

L6(2)<sub>3</sub> (SEQ ID NO: 5)

3'CCUUC|ACAAGGA[AAGCAGGAGUGCCUGAGUAGUC]GUCGCCG 5'

L6(2)<sub>4</sub> (SEQ ID NO: 6).

Cleavage of the substrate *in vitro* using L6(2)<sub>0</sub> resulted in complete cleavage of both the L6 and the K28 substrate at the expected cleavage site.

L6(2)<sub>2</sub> cleaved the L6 substrate, albeit inefficiently. Inefficient cleavage of the K28 substrate was also observed. An increase of the molar ratio of ribosome with respect to substrate increased the efficiency of the cleavage reaction; however, it remained nonspecific.

L6(2)<sub>3</sub> and L6(2)<sub>4</sub> did not detectably cleave either the K28 or L6 substrate.

The L6(2) class of hammerhead ribozymes is comprised of a sequence complementary to *bcr* exon 2, the hammerhead catalytic core and two regions that are complementary to *abl* exon 2. The region on *bcr* exon 2, to which the anchor is complementary, is contiguous with the region of substrate RNA complementary to one of the legs. The first *abl* complementary region is located at the extreme 5' end of the ribozyme while the second region of *abl* complementarity is situated immediately 3' to the catalytic sequence. The sequence of this region varies in each of the ribozymes of the series. The L6(2)<sub>0</sub> ribozyme maintains perfect complementarity to *abl* exon 2, and ribozymes, L6(2)<sub>2</sub>, L6(2)<sub>3</sub> and L6(2)<sub>4</sub>, contain 2, 3, or 4 mismatches, respectively, to the *abl* exon 2 sequence.

These ribozymes have been designed to cleave at the CUU triplet located 7 nt 3' of the *bcr-abl* junction. Cleavage at this site in the synthetic substrate results in the generation of two fragments which are 131 nts and 97 nts in length (consisting of 65 or 85 nucleotides of substrate and 66 or 12 nucleotides of polylinker, respectively). Although both the L6(2)<sub>0</sub> and L6(2)<sub>2</sub> ribozymes cleaved the synthetic L6 substrate into the expected cleavage products, the L6(2)<sub>0</sub> ribozyme was more active. Unexpectedly, both ribozymes were also able to correctly cleave a synthetic K28

- 37 -

substrate as efficiently as they cleaved the L6 substrate. The L6(2)<sub>3</sub> and L6(2)<sub>4</sub> ribozymes had no detectable activity.

The L6(2)<sub>0</sub> ribozyme is more active than the L6(1)<sub>31</sub> ribozyme, but less active than both the 21 nt and 11 nt anchored ribozymes of Example 1 at time points analyzed between 0.5 and 4 hours. By 8 hours however, L6(2)<sub>0</sub> had cleaved more substrate than the 21 nt anchored ribozyme.

These ribozymes were specific for *bcr-abl* mRNA but were not as active as the L6(1) ribozymes in cleavage analyzed at early time points. The L6(1) ribozymes contained a spacer and longer anchor sequences. The lower activity of the L6 (2) ribozymes was, in part, due to reduced substrate binding as is demonstrated by the gel shift assay. These ribozymes appeared to bind significantly to only one of the conformational species of the L6 *bcr-abl* substrate. However, most of the substrate was cleaved by the L6(2)<sub>0</sub> ribozyme after 8 hours suggesting that the secondary structure of the substrate may not be static and may shift into another conformation that allows ribozyme binding. This demonstrated one advantage of anchored ribozymes--maintaining the cleavage core in proximity so that when conformational shifts make target sites otherwise unavailable available.

The secondary structure predictions indicate that the cleavage site and flanking *abl* sequence recognized by the L6 (2) ribozymes may not be accessible to these ribozymes (Figure 6b). However, a region of *bcr* complementary to the 3' end of the ribozymes as well as one nucleotide of *abl* does appear to be accessible in the predicted RNA conformation. This region may not be available in the second conformational species of the L6 substrate RNA that is not bound by the ribozymes.

Although L6(2)<sub>3</sub> and L6(2)<sub>4</sub> did not appear active in the present testing, they may respond differently if synthesized chemically without polylinker sequences. The L6(2)<sub>0</sub> and L6(2)<sub>2</sub> ribozymes were also able to cleave a synthetic K28 substrate as efficiently as they cleaved the

- 38 -

L6 substrate. The ribozymes according to the invention are the first reported to specifically cleave both the L6 and the K28 fusion MRNAs and thus could potentially be used as a single therapeutic to treat cases of CML associated with either a K28 or L6 type translocation.

### Example 3 - Specificity and Efficiency

The specificity of the ribozymes for *bcr-abl* mRNA was tested by incubating the ribozymes with a synthetic normal *abl* substrate (Figure 5a) or a synthetic normal *bcr* substrate (Figure 5b). Ten pmol each of the ribozyme and a mixture of radiolabelled and non-radiolabelled substrate were incubated at 37°C for 6 hours and subjected to denaturing gel electrophoresis on a 5% polyacrylamide gel. In Figure 5a, Lanes 1-6 represent ribozymes L6(1)<sub>31</sub>, L6(1)<sub>21</sub>, L6(1)<sub>11</sub>, L6(2)<sub>0</sub>, L6(2)<sub>2</sub>, and L6(2)<sub>3</sub>, respectively. Lane 7 contained no ribozyme. In Figure 5b, Lanes 1-5 were as described for Figure 5a. Lane 6 contained no ribozyme. No cleavage products were detected in any of these reactions indicating that these ribozymes are all specific for *bcr-abl* mRNA. An anchor-minus L6(1) ribozyme (SEQ ID NO:23) also failed to cleave the normal *abl* substrate.

Cleavage of normal *bcr* was not anticipated as this molecule lacks the target cleavage site, however, this target site is present in the normal *abl* substrate. Failure of the ribozymes to cleave this molecule may have been due to the inability of the ribozymes to bind to the normal *abl* substrate or to the inability of the ribozymes to cleave the molecule once bound to it. In order to discriminate between these two possibilities, a substrate gel shift assay was performed.

Gel shift experiments were performed with either a radiolabelled L6 *bcr-abl* substrate or a radiolabelled normal *abl* substrate. Two predominant conformational species of the L6 *bcr-abl* RNA exist under the assay conditions. Both of these species are shifted by the L6(1) ribozymes. In contrast, the L6 (2)<sub>0</sub> and the L6(2)<sub>2</sub> ribozymes were only able



- 39 -

to shift the faster migrating species of *bcr-abl* RNA. None of the ribozymes tested was able to shift the radiolabelled *abl* substrate which migrates as one conformational species on a native gel. This result indicates that the specificity of these ribozymes for the *bcr-abl* substrate was due to the inability of these ribozymes to bind to the normal *abl* substrate.

A kinetic analysis was performed to identify ribozymes with higher rates of reaction. The 21 nt and 11 nt-anchored ribozymes were initially chosen for further analysis because they exhibited specificity and the highest rates of cleavage at the early time points. This analysis would also enable us to determine the effect of anchor length on ribozyme activity.

All experiments were carried out under conditions of substrate excess. Cleavage rates were determined for the 11 and 21 nt anchored ribozymes. Figure 7a depicts the testing of  $L6(1)_{11}$  at  $\bullet$  2:1;  $\circ$  5:1;  $\square$  10:1, substrate to ribozyme ratio. Figure 7b depicts the testing of  $L6(1)_{21}$  at the same substrate to ribozyme ratios as for  $L6(1)_{11}$  above. Figure 7c is a comparison of  $\square$   $L6(1)_{11}$  and  $\bullet$   $L6(1)_{21}$  at a 5:1 ratio of substrate to ribozyme. Analysis of the results suggested that these reactions did not follow Michaelis-Menton kinetics (Haseloff, et al., Nature 1988, 334, 585-591). The data was therefore fitted to pseudo-first-order kinetics by plotting the ratio of the concentrations of product and ribozyme against time. Reaction rates were obtained from the linear regression of the reaction time course using the "Enzyfitter" program (Elsevier Biosoft).

Both ribozymes exhibited a burst of product formation at early time points followed by a much slower steady state rate. The slope of the initial burst indicates the catalytic rate to be 0.03/min for each ribozyme. The slope at later timepoints indicates the dissociation rates of the products from the ribozyme. Similar slopes were observed at the various ribozyme to substrate ratios for a given ribozyme. However, at all substrate to ribozyme

- 40 -

ratios tested, the 21 nt anchored ribozyme exhibited a 3- to 4-fold slower turnover than the 11 nt ribozyme as indicated by the differences between the two slopes.

#### Example 4

#### 5 K28 - L6 Combination Treatment

##### Cells

K562 cells were obtained from the American Type Tissue Culture Collection and were passaged at a cell density of  $10^5$ /ml in a  $\alpha$  modification MEM medium (JRH Biosciences) adjusted to 10% fetal bovine serum (Gibco-BRL) 1 mM sodium pyruvate (JRH Biosciences), 1 X non-essential amino-acids (JRH Biosciences) and 2 mM glutamine (JRH Biosciences).

An 18-mer (SEQ ID NO: 7) 5'GAAGGGCTTTTGAAGTCT 3' phosphorothioate antisense oligonucleotide spanning the K28 junction of the K28 fusion mRNA and an 18-mer (SEQ ID NO: 8) 5'TACGCGATTACGTTGAGT 3'phosphorothioate scrambled oligonucleotide of the same base composition as the K28 antisense oligonucleotide were purchased from Synthecell.

20 An 18-mer (SEQ ID NO: 9) 5'GAAGGGCTTCTTCCTTAT 3'phosphodiester antisense oligonucleotide spanning the fusion of the L6 junction mRNA and an 18-mer (SEQ ID NO: 10) 5'TATTCCTTCTTCGGAAG 3'phosphodiester oligonucleotide having the same base composition as the L6 antisense molecule in anti-parallel orientation were synthesized on a Milligen BioSearch 8750 DNA synthesizer, as a sianoeethylphosphoroamidite synthesis (Tetrahedron Lett. 1981, 22, 1859-1862).

K562 cells were harvested for plating at 48 hours post passage, a time at which cells have been determined to be in exponential growth. Cells were pelleted, washed and resuspended in Opti-MEM (BRL-Gibco) at a cell density of  $1 \times 10^6$ /ml and plated in 96 well plates at a density of  $5 \times 10^4$  cell/well.

- 41 -

One hundred  $\mu$ l of a mix containing 2  $\mu$ g of lipofectin (BRL) and either 10  $\mu$ g of a single oligonucleotide or 10  $\mu$ g of each of two oligonucleotides in Opti-MEM were added per well. Untreated control cells  
5 received 100  $\mu$ l Opti-MEM alone; the cells were incubated at 37°C for 4 hours, at which time 50  $\mu$ l of heat-inactivated 40% fetal bovine serum (Gibco-BRL) was added per well. Twenty hours post lipofection, 5  $\mu$ g of the appropriate oligonucleotide or 5  $\mu$ g of each two oligonucleotides in 25  
10  $\mu$ l of Opti-MEM were added to the designated wells.

At each time point, 20  $\mu$ l of a 1:30 dilution of  $^3$ H-thymidine (6.7 ci/mMol) was added to each of the appropriate wells. The cells were incubated at 37°C for 18 hours and then harvested and lysed on an automatic cell harvester  
15 (Skatron) according to manufacturers directions. DNA was collected on Skatron filtermats. The filters were dried, placed in scintillation vials with 3 mls ECO-Scint (National Diagnostics) and counted in a Beckman LS 9800 scintillation counter.

20 The effect of the K28 or combination K28/L6 antisense treatments on cell division was measured and compared to the effect obtained using a scrambled oligonucleotide having the same nucleotide content. A decrease in  $^3$ H-thymidine uptake by K562 cells treated with  
25 the L6-specific antisense was observed at 4 hours after the first antisense treatment (Table 1, Timepoint 1) and this trend was continued at all timepoints. A decrease in the  $^3$ H-thymidine incorporation by cells treated with a mixture of the K28 and L6 antisense compounds was also observed at all  
30 timepoints (Table 1). The magnitude of the effect varied at each timepoint, and the largest difference was observed at Timepoint 4. The combination treatment with the L-6 and K28 oligonucleotides resulted in a 1.6 to 3.9-fold reduction of  $^3$ H-thymidine uptake relative to that observed with the  
35 scrambled control (Table 1). Treatment with the L6 oligonucleotide alone resulted in a 3.1 to 4.8-fold reduction of  $^3$ H-thymidine uptake relative to that observed

- 42 -

with the scrambled control (Table 1). Treatment with the K28 antisense alone resulted in only a slight reduction of <sup>3</sup>H-thymidine uptake relative to control uptake at Timepoints 2 and 3 (Table 1). A comparison between the values obtained for the untreated control samples and any of the treated samples indicates that non-specific toxicity occurred as a result of either lipofection or a combination of lipofection and oligonucleotide treatment.

The effect of antisense treatment on cellular morphology was also examined. The untreated and treated cells looked similar when examined at Timepoints 1 and 2. However, cells having large vacuoles that occupied the majority of the cellular volume were present in the samples treated with the L6 antisense alone and the L6/K28 combination at Timepoint 3. The percentage of cells having the vacuolar appearance was greatest at Timepoint 4 in each case. Cells having the vacuolar appearance were not observed in the untreated sample, in the sample treated with the K28 antisense oligonucleotide, or in the sample treated with any of the scrambled oligonucleotides. Therefore, there was a correlation between decreased <sup>3</sup>H-thymidine uptake and the vacuolar morphology.

These results indicate that treatment of the K562 cell line with an L6-specific or a combination of the L6 and K28-specific antisense oligonucleotides decreased the growth rate of the K562 cell line. Treatment with the K28-specific oligonucleotide did not significantly decrease the growth rate of the K562 cell line, unlike the results reported in Szczylik et al., *Science* 1991, 253, 562-565, wherein decrease in leukemic colony formation was observed after treatment with a similar K28-specific antisense oligonucleotide having a phosphodiester backbone.

- 43 -

TABLE 1

OLIGONUCLEOTIDE		TIMEPOINT			
		1	2	3	4
	K28	179610	172220	120422	133225
5	K28 scrambled	180635	209980	141250	121580
	L6	51148	39136	10109	7923
	L6 scrambled	244680	93215	39468	24887
	K28 + L6	99132	77300	35048	20156
	K28 + L6 scrambled	158410	154240	108445	78045
10	untreated	261520	302410	439550	458780

Timepoint 1: Cells pulsed with  $^3\text{H}$ -thymidine at 4 hours post lipofection.

Timepoint 2: Cells pulsed with  $^3\text{H}$ -thymidine at 22 hours post lipofection.

15 Timepoint 3: Cells pulsed with  $^3\text{H}$ -thymidine at 28 hours post lipofection.

Timepoint 4: Cells pulsed with  $^3\text{H}$ -thymidine at 53 hours post lipofection.

20 The foregoing examples were meant to illustrate the invention and not to limit it in anyway. Those skilled in the art will recognize that modifications can be made which are within the spirit and scope of the invention as set forth in the appended claims.

- 44 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Pachuk et al.
- (ii) TITLE OF INVENTION: Compounds and Methods for the Treatment of Leukemias
- (iii) NUMBER OF SEQUENCES: 23
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Woodcock Washburn  
Kurtz Mackiewicz & Norris
  - (B) STREET: One Liberty Place - 46th Floor
  - (C) CITY: Philadelphia
  - (D) STATE: PA
  - (E) COUNTRY: USA
  - (F) ZIP: 19103
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
  - (B) COMPUTER: IBM PS/2
  - (C) OPERATING SYSTEM: PC-DOS
  - (D) SOFTWARE: WORDPERFECT 5.1
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: n/a
  - (B) FILING DATE: Herewith
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 07/989,852
  - (B) FILING DATE: December 4, 1992
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Doreen Yatko Trujillo
  - (B) REGISTRATION NUMBER: 35,719
  - (C) REFERENCE/DOCKET NUMBER: APOL-0019
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (215) 568-3100
  - (B) TELEFAX: (215) 568-3439

## (2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 62

- 45 -

- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CACAGCAUUC CGCUGACCAU CAAUAAGGAA GAAGCCCUUC AGCGGCCAGU  
AGCAUCUGAC UU 62

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 81
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GUCAGAUGCC UGAUGAGUCC GUGAGGACGA AACUGGCAAG AACCCAAAAA  
CUUCCUUAUU GAUGGUCAGC GGAAUGCUGU G 81

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCCGCUGCUG AUGAGUCCGU GAGGACGAAA GGGCUUCUUC C 41

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCCGCUGCUG AUGAGUCCGU GAGGACGAAA GGGCCACUUC C 41

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- 46 -

- (A) LENGTH: 41
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GCCGCUGCUG AUGAGUCCGU GAGGACGAAA GGGACACUUC C 41

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GCCGCUGCUG AUGAGUCCGU GAGGACGAAA GGAACACUUC C 41

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GAAGGGCTTT TGAACCT 18

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

TACGCGATTA CGTTGAGT 18

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:



- 47 -

- (A) LENGTH: 18
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear
- (iv) ANTI-SENSE: Yes
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:  
GAAGGGCTTC TTCCTTAT 18
- (2) INFORMATION FOR SEQ ID NO: 10:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 18
    - (B) TYPE: Nucleic Acid
    - (C) STRANDEDNESS: Single
    - (D) TOPOLOGY: Linear
  - (iv) ANTI-SENSE:
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:  
TATTCCTTCT TCGGGAAG 18
- (2) INFORMATION FOR SEQ ID NO: 11:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 22
    - (B) TYPE: Nucleic Acid
    - (C) STRANDEDNESS: Single
    - (D) TOPOLOGY: Linear
  - (iv) ANTI-SENSE:
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:  
CUGAUGAGUC CGUGAGGACG AA 22
- (2) INFORMATION FOR SEQ ID NO: 12:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 47
    - (B) TYPE: Nucleic Acid
    - (C) STRANDEDNESS: Single
    - (D) TOPOLOGY: Linear
  - (iv) ANTI-SENSE:
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:  
TTCCATGGAG ACGCAGAAGC CCUUCAGCGG CCAGUAGCAU CUGACUU 47
- (2) INFORMATION FOR SEQ ID NO: 13:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 66

- 48 -

- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GUCAGAUGCC UGAUGAGUCC GUGAGGACGA AACUGGCAAG AACCCAAAAA  
CTGCGTCTCC ATGGAA 66

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 61
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GUCAGAUGCC UGAUGAGUCC GUGAGGACGA AACUGGCAAG AACCCAAAAA  
CUUCCUUAU G 61

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 71
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GUCAGAUGCC UGAUGAGUCC GUGAGGACGA AACUGGCAAG AACCCAAAAA  
CUUCCUUAU GAUGGUCAGC G 71

((2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

ATTGCGATAG GATTGAATTC AACTCGTGTG TGAAACTCCA 40

(2) INFORMATION FOR SEQ ID NO: 17:

- 49 -

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 40
  - (B) TYPE: Nucleic Acid
  - (C) STRANDEDNESS: Single
  - (D) TOPOLOGY: Linear
- (iv) ANTI-SENSE:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:  
AATGCGATAG GATTGAATTC GTCCAGCGAG AAGGTTTTCC 40
- (2) INFORMATION FOR SEQ ID NO: 18:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 67
    - (B) TYPE: Nucleic Acid
    - (C) STRANDEDNESS: Single
    - (D) TOPOLOGY: Linear
  - (iv) ANTI-SENSE:
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:  
ATTGCGATAG GATTGAATTC AAGCTTAAGT GTTTCAGAAG CTTCTCCCTG  
ACATCCGTGG AGCTGCA 67
- (2) INFORMATION FOR SEQ ID NO: 19:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 61
    - (B) TYPE: Nucleic Acid
    - (C) STRANDEDNESS: Single
    - (D) TOPOLOGY: Linear
  - (iv) ANTI-SENSE:
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:  
AATGCGATAG GATTGAATTC CGGAGACTCA TCATCTTCCT TATTGATGGT  
CAGCGGAATG C 61
- (2) INFORMATION FOR SEQ ID NO: 20:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 23
    - (B) TYPE: Nucleic Acid
    - (C) STRANDEDNESS: Single
    - (D) TOPOLOGY: Linear
  - (iv) ANTI-SENSE:
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:  
TAGGACTGCT CTCACCTTCTC ACG 23

- 50 -

## (2) INFORMATION FOR SEQ ID NO: 21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

## (iv) ANTI-SENSE:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

ATCTGCCTGA AGCTGGTGGG CTGC 24

## (2) INFORMATION FOR SEQ ID NO: 22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

## (iv) ANTI-SENSE:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

ATGCTTAGAG TGTTATCTCC ACT 23

## (2) INFORMATION FOR SEQ ID NO: 23:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50
- (B) TYPE: Nucleic Acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

## (iv) ANTI-SENSE:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

GUCAGAUGCC UGAUGAGUCC GUGAGGACGA AACUGGCAAG AACCCAAAAA 50

What is claimed is:

1. A ribozyme capable of cleaving a substrate mRNA comprising:

a catalytic sequence;

5 two legs, one on each side of the catalytic sequence and substantially complementary with the substrate mRNA; and

at least one anchor sequence complementary to the substrate mRNA.

10

2. A ribozyme capable of cleaving a substrate mRNA comprising:

a catalytic sequence;

15 two legs, one on each side of the catalytic sequence and substantially complementary with the substrate mRNA; and

at least one anchor sequence complementary to the substrate mRNA at a location that is noncontiguous with the portions of the substrate mRNA complementary to the legs.

20

3. The ribozyme of claim 1 wherein the portion of the substrate mRNA that is complementary with the anchor sequence is located at least about 3 nucleotides away from the portions of the substrate mRNA that are complementary with the legs.

25

4. The ribozyme of claim 1 further comprising a spacer region between a leg and the anchor, wherein said spacer region does not substantially hybridize to the mRNA substrate sequences located between an area of complementarity with the anchor and an area of  
30 complementarity with a leg of the ribozyme.

5. The ribozyme of claim 3 wherein the spacer region comprises nucleotides, or derivatives thereof.

- 52 -

6. The ribozyme of claim 3 wherein the spacer region comprises a polyalkylene glycol.

7. The ribozyme of claim 4 wherein the spacer region comprises from about 1 to about 3000 nucleotides, or  
5 derivatives thereof.

8. The ribozyme of claim 3 wherein the spacer region comprise a chemical spacer of a size equivalent to from about 1 to about 3000 nucleotides.

9. The ribozyme of claim 6 wherein the spacer  
10 region comprises at least about 13 nucleotides, or derivatives thereof.

10. The ribozyme of claim 1 wherein each leg has at least about 4 nucleotides and the anchor region has at least about 2 nucleotides.

15 11. A ribozyme capable of cleaving an L6 mRNA having *bcr* exon 2 sequences fused at a junction to *abl* exon 2 sequences comprising nucleotides, or derivatives thereof, having at least one region complementary to *bcr* exon 2, at least one region complementary to *abl* exon 2, and at least  
20 one catalytic sequence capable of cleaving the L6 mRNA.

12. The ribozyme of claim 10 wherein said ribozyme is also capable of cleaving a K28 mRNA.

13. The ribozyme of claim 11 comprising  
GCCGCUGCUGAUGAGUCCGUGAGGACGAAAGGGCUUCUCC (SEQ ID NO: 3) or  
25 derivatives thereof.

14. The ribozyme of claim 10 wherein the catalytic sequence is capable of cleaving sequences in *abl* exon 2.

- 53 -

15. The ribozyme of claim 10 having at least 2 regions of complementarity to *abl* exon 2, at least one located 5' and at least one located 3' of the catalytic sequence.

5           16. The ribozyme of claim 10 wherein the catalytic sequence comprises the sequence CUGAUGAGUCCGUGAGGACGAA (SEQ ID NO: 11) or derivatives thereof.

10           17. The ribozyme of claim 13 wherein the ribozyme comprises a sequence selected from the group consisting of  
GUCAGAUGCCUGAUGAGUCCGUGAGGACGAAACUGGCAAGAACCCAAAAACUCCUUAUU  
GAUGGUCAGCGGAAUGCUGUG (SEQ ID NO: 2),  
GUCAGAUGCCUGAUGAGUCCGUGAGGACGAAACUGGCAAGAACCCAAAAACUCCUUAUU  
GAUGGUCAGCG (SEQ ID NO: 15),  
15 GUCAGAUGCCUGAUGAGUCCGUGAGGACGAAACUGGCAAGAACCCAAAAACUCCUUAUU  
G (SEQ ID NO: 14),  
GCCGCUGCUGAUGAGUCCGUGAGGACGAAAGGGCUUCUUC (SEQ ID NO: 3),  
GCCGCUGCUGAUGAGUCCGUGAGGACGAAAGGGCCACUUC (SEQ ID NO: 4),  
and derivatives thereof.

20           18. The ribozyme of claim 13 wherein the region complementary to *bcr* exon 2 comprises from about 5 to about 31 nucleotides or derivatives thereof.

19. The ribozyme of claim 10 wherein the region complementary to *abl* exon 2 comprises from about 10 to about  
25 15 nucleotides or derivatives thereof.

20. The ribozyme of claim 10 further comprising a spacer region which does not substantially hybridize to the substrate mRNA sequences between the anchor and a leg.

21. The ribozyme of claim 20 wherein the spacer  
30 region comprises at least about 13 nucleotides.

- 54 -

22. The ribozyme of claim 10 wherein the cleavage occurs at a CUU site.

23. The ribozyme of claim 10 wherein the cleavage occurs at a GUA site.

5           24. A method of treating a vertebrate suspected of having hematopoietic cells that express L6 mRNA, comprising administering to the vertebrate at least one oligonucleotide therapeutic capable of decreasing expression of L6 mRNA.

10           25. A method of treating a vertebrate suspected of having hematopoietic cells that express L6 mRNA, comprising administering to the vertebrate at least one oligonucleotide therapeutic capable of decreasing expression of both the L6 and K28 mRNAs.

15           26. The method of claim 24 or 25 wherein the vertebrate is suspected of having CML or ALL.

27. The method of claim 24 or 25 wherein the oligonucleotide therapeutic comprises a ribozyme of claim 1.

20           28. The method of claim 27 further comprising a ribozyme capable of cleaving K28 mRNA.

29. The method of claim 27 wherein the ribozyme comprises a sequence selected from the group consisting of  
GUCAGAUGCCUGAUGAGUCCGUGAGGACGAAACUGGCAAGAACCCAAAAACUCCUUAUU  
GAUGGUCAGCGGAUAGCUGUG (SEQ ID NO: 2),  
25 GUCAGAUGCCUGAUGAGUCCGUGAGGACGAAACUGGCAAGAACCCAAAAACUCCUUAUU  
G (SEQ ID NO:14),  
GUCAGAUGCCUGAUGAGUCCGUGAGGACGAAACUGGCAAGAACCCAAAAACUCCUUAUU  
GAUGGUCAGCG (SEQ ID NO:15),  
GCCGCUGCUGAUGAGUCCGUGAGGACGAAAGGGCUUCUUC (SEQ ID NO: 3),  
30 GCCGCUGCUGAUGAGUCCGUGAGGACGAAAGGGCCACUUC (SEQ ID NO: 4),



and derivatives thereof.

30. The method of claim 26 wherein the  
oligonucleotide therapeutic further comprises an antisense  
oligonucleotide, or derivatives thereof, capable of binding  
5 to L6 mRNA.



31. The method of claim 26 wherein the  
oligonucleotide therapeutic further comprises an antisense  
oligonucleotide, or derivatives thereof, capable of binding  
to K28 mRNA.


10 32. The method of claim 24 or 25 further  
comprising *ex vivo* administration of the oligonucleotide  
therapeutic.

33. A method of treating a vertebrate suspected  
of having hematopoietic cells that express c-myc and at  
15 least one of L6 and K28 mRNAs, comprising administering to  
the vertebrate an oligonucleotide therapeutic capable of  
decreasing expression of c-myc mRNA and an oligonucleotide  
therapeutic capable of decreasing expression of at least one  
of K28 mRNA and L6 mRNA.


20 34. A ribozyme capable of cleaving an L6 mRNA  
having *bcr* exon 2 sequences fused at a junction to *abl* exon  
2 sequences.

1/9





**Fig. 2**



**Fig. 3**




FIG. 4A

FIG. 4B

FIG. 4C




FIG. 5A






FIG. 5B






**Fig. 6A**





8/9

***Fig. 7A******Fig. 7B***



*Fig. 7C*

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/11144

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : C12N 15/00; C07H 17/00; A61K 48/00

US CL : 435/172.1; 536/24.1; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC.

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/172.1; 536/24.1; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X - Y	EP, A1, 0,421,376 (MULLNER et al.) 10 April 1990, see abstract.	1-5, 7, 9-10, 34 ----- 6, 8, 11-33
X - Y	WO, A1, 92/00080 (REDDY) 09 January 1992, see page 11.	11-19, 22-23, 34 ----- 1-10, 20-21, 24-33
Y	WO, A1, 89/05852 (HASELOFF et al.) 29 June 1989, see page 4 and Figures 10 and 15.	1-34



Further documents are listed in the continuation of Box C.



See patent family annex.

Special categories of cited documents:		*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A	document defining the general state of the art which is not considered to be part of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E	earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G	document member of the same patent family
*O	document referring to an oral disclosure, use, exhibition or other means		
*P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

11 January 1994

Date of mailing of the international search report

07 MAR 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

KATHLEEN L. CHOI

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

Int. national application No.  
PCT/US93/11144

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Cell, Volume 47, issued 1986, E. Shtivelman et al., "Alternative Splicing of RNAs Transcribed from the Human <u>abl</u> Gene and from the <u>bcr-abl</u> Fused Gene", pages 277-284, see pages 280-282.	1-34
Y	US, A, 4,914,210 (LEVENSON et al.) 03 April 1990, see columns 4, 12-18.	6, 8
Y	Proceedings in National Academy of Science, U.S.A., Volume 84, issued 1987, C.Y. Wang et al., "pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse", pages 7851-7855, see entire document.	24-33

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**